Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides

Nucleic Acids Research

Volumn 44, Issue 2, 2016, Pages 863-877

  Lennox, Kim A ^a   Behlke, Mark A ^a  

^a INTEGRATED DNA TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CANCER SUSCEPTIBILITY CANDIDATE 7; DIFFERENTIATION ANTAGONIZING NON PROTEIN CODING RNA; HOX TRANSCRIPT ANTISENSE RNA; LONG UNTRANSLATED RNA; METASTASIS ASSOCIATED IN LUNG ADENOCARCINOMA TRANSCRIPT 1; NUCLEAR ENRICHED ABUNDANT TRANSCRIPT 1; OIP5 ANTISENSE RNA 1; TAURINE UPREGULATED GENE 1; UNCLASSIFIED DRUG; DANCR LONG NON-CODING RNA, HUMAN; HOTAIR LONG UNTRANSLATED RNA, HUMAN; MALAT1 LONG NON-CODING RNA, HUMAN; NEAT1 LONG NON-CODING RNA, HUMAN; TUG1 LONG NONCODING RNA, HUMAN;

ARTICLE; CELL COMPARTMENTALIZATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOPLASM; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE METABOLISM; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE; GENETICS; HCT 116 CELL LINE; HELA CELL LINE; METABOLISM; PROCEDURES;

CELL NUCLEUS; CYTOPLASM; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HELA CELLS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA, LONG NONCODING;

EID: 84966430344     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv1206     Document Type: Article

References (117)

1. Derrien,T., Johnson,R., Bussotti,G., Tanzer,A., Djebali,S., Tilgner,H., Guernec,G., Martin,D., Merkel,A., Knowles,D.G. et al. (2012) The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res., 22, 1775-1789.
2. Iyer,M.K., Niknafs,Y.S., Malik,R., Singhal,U., Sahu,A., Hosono,Y., Barrette,T.R., Prensner,J.R., Evans,J.R., Zhao,S. et al. (2015) The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet., 47, 199-208.
3. Di Gesualdo,F., Capaccioli,S. and Lulli,M. (2014) A pathophysiological view of the long non-coding RNA world. Oncotarget, 5, 10976-10996.
4. Dey,B.K., Mueller,A.C. and Dutta,A. (2014) Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription, 5, e944014.
5. Rossi,M.N. and Antonangeli,F. (2014) LncRNAs: New Players in Apoptosis Control. Int. J. Cell Biol., 2014, e473857.
6. Cao,J. (2014) The functional role of long non-coding RNAs and epigenetics. Biol.Proced.Online, 16, e11.
7. Rinn,J.L. and Chang,H.Y. (2012) Genome regulation by long noncoding RNAs. Annu. Rev. Biochem., 81, 145-166.
8. Kornienko,A.E., Guenzl,P.M., Barlow,D.P. and Pauler,F.M. (2013) Gene regulation by the act of long non-coding RNA transcription. BMC Biol., 11, e59.
9. Nie,L., Wu,H.J., Hsu,J.M., Chang,S.S., Labaff,A.M., Li,C.W., Wang,Y., Hsu,J.L. and Hung,M.C. (2012) Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am. J. Transl. Res., 4, 127-150.
10. Niland,C.N., Merry,C.R. and Khalil,A.M. (2012) Emerging roles for long non-coding rnas in cancer and neurological disorders. Front. Genet., 3, e25.
11. Kunej,T., Obsteter,J., Pogacar,Z., Horvat,S. and Calin,G.A. (2014) The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring. Crit. Rev. Clin. Lab. Sci., 51, 344-357.
12. Weber,D.G., Johnen,G., Casjens,S., Bryk,O., Pesch,B., Jockel,K.H., Kollmeier,J. and Bruning,T. (2013) Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res. Notes, 6, e518.
13. Ulitsky,I. and Bartel,D.P. (2013) lincRNAs: genomics, evolution, and mechanisms. Cell, 154, 26-46.
14. Ma,L., Bajic,V.B. and Zhang,Z. (2013) On the classification of long non-coding RNAs. RNA Biol., 10, 925-933.
15. van Heesch,S., van Iterson,M., Jacobi,J., Boymans,S., Essers,P.B., de Bruijn,E., Hao,W., MacInnes,A.W., Cuppen,E. and Simonis,M. (2014) Extensive localization of long noncoding RNAs to the cytosol and mono- and polyribosomal complexes. Genome Biol., 15,R6.
16. Cabili,M.N., Dunagin,M.C., McClanahan,P.D., Biaesch,A., Padovan-Merhar,O., Regev,A., Rinn,J.L. and Raj,A. (2015) Localization and abundance analysis of human lncRNAs at single-cell and single-molecule resolution. Genome Biol., 16, e20.
17. Stephenson,M.L. and Zamecnik,P.C. (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U.S.A., 75, 285-288.
18. Inoue,H., Hayase,Y., Iwai,S. and Ohtsuka,E. (1987) Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. Nucleic Acids Symp. Ser., 18, 221-224.
19. Monia,B.P., Lesnik,E.A., Gonzalez,C., Lima,W.F., McGee,D., Guinosso,C.J., Kawasaki,A.M., Cook,P.D. and Freier,S.M. (1993) Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem., 268, 14514-14522.
20. Wu,H., Lima,W.F., Zhang,H., Fan,A., Sun,H. and Crooke,S.T. (2004) Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem., 279, 17181-17189.
21. Suzuki,Y., Holmes,J.B., Cerritelli,S.M., Sakhuja,K., Minczuk,M., Holt,I.J. and Crouch,R.J. (2010) An upstream open reading frame and the context of the two AUG codons affect the abundance of mitochondrial and nuclear RNase H1. Mol. Cell. Biol., 30, 5123-5134.
22. Vickers,T.A., Koo,S., Bennett,C.F., Crooke,S.T., Dean,N.M. and Baker,B.F. (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem., 278, 7108-7118.
23. Prasanth,K.V., Prasanth,S.G., Xuan,Z., Hearn,S., Freier,S.M., Bennett,C.F., Zhang,M.Q. and Spector,D.L. (2005) Regulating gene expression through RNA nuclear retention. Cell, 123, 249-263.
24. Wheeler,T.M., Leger,A.J., Pandey,S.K., MacLeod,A.R., Nakamori,M., Cheng,S.H., Wentworth,B.M., Bennett,C.F. and Thornton,C.A. (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature, 488, 111-115.
25. Chiang,M.Y., Chan,H., Zounes,M.A., Freier,S.M., Lima,W.F. and Bennett,C.F. (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem., 266, 18162-18171.
26. Zamecnik,P.C. and Stephenson,M.L. (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A., 75, 280-284.
27. Eder,P.S., DeVine,R.J., Dagle,J.M. and Walder,J.A. (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res. Dev., 1, 141-151.
28. Lennox,K.A., Owczarzy,R., Thomas,D.M., Walder,J.A. and Behlke,M.A. (2013) Improved performance of anti-mirna oligonucleotides using a novel non-nucleotide modifier. Mol. Ther. Nucleic Acids., 2, e117.
29. Kurreck,J. (2003) Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem., 270, 1628-1644.
30. Inoue,H., Hayase,Y., Iwai,S. and Ohtsuka,E. (1987) Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett., 215, 327-330.
31. Shibahara,S., Mukai,S., Nishihara,T., Inoue,H., Ohtsuka,E. and Morisawa,H. (1987) Site-directed cleavage of RNA. Nucleic Acids Res., 15, 4403-4415.
32. Prakash,T.P. (2011) An overview of sugar-modified oligonucleotides for antisense therapeutics. Chem. Biodivers, 8, 1616-1641.
33. Lennox,K.A., Sabel,J.L., Johnson,M.J., Moreira,B.G., Fletcher,C.A., Rose,S.D., Behlke,M.A., Laikhter,A.L., Walder,J.A. and Dagle,J.M. (2006) Characterization of modified antisense oligonucleotides in Xenopus laevis embryos. Oligonucleotides, 16, 26-42.
34. Gupta,N., Fisker,N., Asselin,M.C., Lindholm,M., Rosenbohm,C., Orum,H., Elmen,J., Seidah,N.G. and Straarup,E.M. (2010) A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One, 5, e10682.
35. Dorsett,Y. and Tuschl,T. (2004) siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov., 3, 318-329.
36. Elbashir,S.M., Harborth,J., Lendeckel,W., Yalcin,A., Weber,K. and Tuschl,T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
37. Kim,D.H., Behlke,M.A., Rose,S.D., Chang,M.S., Choi,S. and Rossi,J.J. (2005) Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol., 23, 222-226.
38. Rose,S.D., Kim,D.H., Amarzguioui,M., Heidel,J.D., Collingwood,M.A., Davis,M.E., Rossi,J.J. and Behlke,M.A. (2005) Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res., 33, 4140-4156.
39. Snead,N.M., Wu,X., Li,A., Cui,Q., Sakurai,K., Burnett,J.C. and Rossi,J.J. (2013) Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants. Nucleic Acids Res., 41, 6209-6221.
40. Behlke,M.A. (2008) Chemical modification of siRNAs for in vivo use. Oligonucleotides, 18, 305-320.
41. Modarresi,F., Faghihi,M.A., Lopez-Toledano,M.A., Fatemi,R.P., Magistri,M., Brothers,S.P., van der Brug,M.P. and Wahlestedt,C. (2012) Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat. Biotechnol., 30, 453-459.
42. Ideue,T., Cho,Y., Nishimura,K. and Tani,T. (2014) Involvement of satellite I noncoding RNA in regulation of chromosome segregation. Genes Cells, 19, 528-538.
43. Ideue,T., Hino,K., Kitao,S., Yokoi,T. and Hirose,T. (2009) Efficient oligonucleotide-mediated degradation of nuclear noncoding RNAs in mammalian cultured cells. RNA, 15, 1578-1587.
44. Zong,X., Huang,L., Tripathi,V., Peralta,R., Freier,S.M., Guo,S. and Prasanth,K.V. (2015) Knockdown of nuclear-retained long noncoding RNAs using modified DNA antisense oligonucleotides. Methods Mol. Biol., 1262, 321-331.
45. Gagnon,K.T., Li,L., Chu,Y., Janowski,B.A. and Corey,D.R. (2014) RNAi factors are present and active in human cell nuclei. Cell Rep., 6, 211-221.
46. Lima,W.F., Wu,H. and Crooke,S.T. (2008) Antisense Drug Technology, Principles, Strategies, and Applications. CRC Press, Boca Raton, Vol. 2, pp. 47-74.
47. Wu,H., Sun,H., Liang,X., Lima,W.F. and Crooke,S.T. (2013) Human RNase H1 is associated with protein P32 and is involved in mitochondrial pre-rRNA processing. PLoS One, 8, e71006.
48. Vickers,T.A. and Crooke,S.T. (2014) Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms. PLoS One, 9, e108625.
49. Kole,R., Vacek,M. and Williams,T. (2004) Modification of alternative splicing by antisense therapeutics. Oligonucleotides, 14, 65-74.
50. Castel,S.E. and Martienssen,R.A. (2013) RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond. Nat. Rev. Genet., 14, 100-112.
51. Stalder,L., Heusermann,W., Sokol,L., Trojer,D., Wirz,J., Hean,J., Fritzsche,A., Aeschimann,F., Pfanzagl,V., Basselet,P. et al. (2013) The rough endoplasmatic reticulum is a central nucleation site of siRNA-mediated RNA silencing. EMBO J., 32, 1115-1127.
52. Martinez,J., Patkaniowska,A., Urlaub,H., Luhrmann,R. and Tuschl,T. (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell, 110, 563-574.
53. Zeng,Y. and Cullen,B.R. (2002) RNA interference in human cells is restricted to the cytoplasm. RNA, 8, 855-860.
54. Ross,J.P. and Kassir,Z. (2014) The varied roles of nuclear argonaute-small RNA complexes and avenues for therapy. Mol. Ther. Nucleic Acids., 3, e203.
55. Ikeda,K., Satoh,M., Pauley,K.M., Fritzler,M.J., Reeves,W.H. and Chan,E.K. (2006) Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody. J. Immunol. Methods, 317, 38-44.
56. Liang,X.H., Vickers,T.A., Guo,S. and Crooke,S.T. (2011) Efficient and specific knockdown of small non-coding RNAs in mammalian cells and in mice. Nucleic Acids Res., 39, e13.
57. Ploner,A., Ploner,C., Lukasser,M., Niederegger,H. and Huttenhofer,A. (2009) Methodological obstacles in knocking down small noncoding RNAs. RNA, 15, 1797-1804.
58. Chu,Y., Yue,X., Younger,S.T., Janowski,B.A. and Corey,D.R. (2010) Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res., 38, 7736-7748.
59. Rudel,S., Flatley,A., Weinmann,L., Kremmer,E. and Meister,G. (2008) A multifunctional human Argonaute2-specific monoclonal antibody. RNA, 14, 1244-1253.
60. Weinmann,L., Hock,J., Ivacevic,T., Ohrt,T., Mutze,J., Schwille,P., Kremmer,E., Benes,V., Urlaub,H. and Meister,G. (2009) Importin 8 is a gene silencing factor that targets argonaute proteins to distinct mRNAs. Cell, 136, 496-507.
61. Ohrt,T., Muetze,J., Svoboda,P. and Schwille,P. (2012) Intracellular localization and routing of miRNA and RNAi pathway components. Curr. Top Med. Chem., 12, 79-88.
62. Robb,G.B., Brown,K.M., Khurana,J. and Rana,T.M. (2005) Specific and potent RNAi in the nucleus of human cells. Nat. Struct. Mol. Biol., 12, 133-137.
63. Ohrt,T., Mutze,J., Staroske,W., Weinmann,L., Hock,J., Crell,K., Meister,G. and Schwille,P. (2008) Fluorescence correlation spectroscopy and fluorescence cross-correlation spectroscopy reveal the cytoplasmic origination of loaded nuclear RISC in vivo in human cells. Nucleic Acids Res., 36, 6439-6449.
64. Hemmings-Mieszczak,M., Dorn,G., Natt,F.J., Hall,J. and Wishart,W.L. (2003) Independent combinatorial effect of antisense oligonucleotides and RNAi-mediated specific inhibition of the recombinant rat P2x3 receptor. Nucleic Acids Res., 31, 2117-2126.
65. Tripathi,V., Shen,Z., Chakraborty,A., Giri,S., Freier,S.M., Wu,X., Zhang,Y., Gorospe,M., Prasanth,S.G., Lal,A. et al. (2013) Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet., 9, e1003368.
66. Nakagawa,S., Ip,J.Y., Shioi,G., Tripathi,V., Zong,X., Hirose,T. and Prasanth,K.V. (2012) Malat1 is not an essential component of nuclear speckles in mice. RNA, 18, 1487-1499.
67. Tripathi,V., Ellis,J.D., Shen,Z., Song,D.Y., Pan,Q., Watt,A.T., Freier,S.M., Bennett,C.F., Sharma,A., Bubulya,P.A. et al. (2010) The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol. Cell, 39, 925-938.
68. Hu,L., Wu,Y., Tan,D., Meng,H., Wang,K., Bai,Y. and Yang,K. (2015) Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res., 34, e7.
69. Ji,P., Diederichs,S., Wang,W., Boing,S., Metzger,R., Schneider,P.M., Tidow,N., Brandt,B., Buerger,H., Bulk,E. et al. (2003) MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene, 22, 8031-8041.
70. Wu,X.S., Wang,X.A., Wu,W.G., Hu,Y.P., Li,M.L., Ding,Q., Weng,H., Shu,Y.J., Liu,T.Y., Jiang,L. et al. (2014) MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol. Ther., 15, 806-814.
71. Sunwoo,H., Dinger,M.E., Wilusz,J.E., Amaral,P.P., Mattick,J.S. and Spector,D.L. (2009) MEN epsilon/beta nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles. Genome Res., 19, 347-359.
72. Sasaki,Y.T., Ideue,T., Sano,M., Mituyama,T. and Hirose,T. (2009) MENepsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles. Proc. Natl. Acad. Sci. U.S.A., 106, 2525-2530.
73. Clemson,C.M., Hutchinson,J.N., Sara,S.A., Ensminger,A.W., Fox,A.H., Chess,A. and Lawrence,J.B. (2009) An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol. Cell, 33, 717-726.
74. Hirose,T., Virnicchi,G., Tanigawa,A., Naganuma,T., Li,R., Kimura,H., Yokoi,T., Nakagawa,S., Benard,M., Fox,A.H. et al. (2014) NEAT1 long noncoding RNA regulates transcription via protein sequestration within subnuclear bodies. Mol. Biol. Cell, 25, 169-183.
75. Johnson,R. (2012) Long non-coding RNAs in Huntington's disease neurodegeneration. Neurobiol. Dis., 46, 245-254.
76. Zhang,Q., Chen,C.Y., Yedavalli,V.S. and Jeang,K.T. (2013) NEAT1 long noncoding RNA and paraspeckle bodies modulate HIV-1 posttranscriptional expression. Mbio, 4, e0059612.
77. Michalik,K.M., You,X., Manavski,Y., Doddaballapur,A., Zornig,M., Braun,T., John,D., Ponomareva,Y., Chen,W., Uchida,S. et al. (2014) Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ. Res., 114, 1389-1397.
78. Chow,J.C., Hall,L.L., Clemson,C.M., Lawrence,J.B. and Brown,C.J. (2003) Characterization of expression at the human XIST locus in somatic, embryonal carcinoma, and transgenic cell lines. Genomics, 82, 309-322.
79. Lin,R., Roychowdhury-Saha,M., Black,C., Watt,A.T., Marcusson,E.G., Freier,S.M. and Edgington,T.S. (2011) Control of RNA processing by a large non-coding RNA over-expressed in carcinomas. FEBS Lett., 585, 671-676.
80. Kretz,M., Webster,D.E., Flockhart,R.J., Lee,C.S., Zehnder,A., Lopez-Pajares,V., Qu,K., Zheng,G.X., Chow,J., Kim,G.E. et al. (2012) Suppression of progenitor differentiation requires the long noncoding RNA ANCR. Genes Dev., 26, 338-343.
81. Tong,X., Gu,P.C., Xu,S.Z. and Lin,X.J. (2015) Long non-coding RNA-DANCR in human circulating monocytes: a potential biomarker associated with postmenopausal osteoporosis. Biosci. Biotechnol. Biochem., 79, 732-737.
82. Zhu,L. and Xu,P.C. (2013) Downregulated LncRNA-ANCR promotes osteoblast differentiation by targeting EZH2 and regulating Runx2 expression. Biochem. Biophys. Res. Commun., 432, 612-617.
83. Ulitsky,I., Shkumatava,A., Jan,C.H., Sive,H. and Bartel,D.P. (2011) Conserved function of lincRNAs in vertebrate embryonic development despite rapid sequence evolution. Cell, 147, 1537-1550.
84. Khalil,A.M., Guttman,M., Huarte,M., Garber,M., Raj,A., Rivea Morales,D., Thomas,K., Presser,A., Bernstein,B.E., van Oudenaarden,A. et al. (2009) Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl. Acad. Sci. U.S.A., 106, 11667-11672.
85. Yang,L., Lin,C., Liu,W., Zhang,J., Ohgi,K.A., Grinstein,J.D., Dorrestein,P.C. and Rosenfeld,M.G. (2011) ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell, 147, 773-788.
86. Young,T.L., Matsuda,T. and Cepko,C.L. (2005) The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina. Curr. Biol., 15, 501-512.
87. Han,Y., Liu,Y., Gui,Y. and Cai,Z. (2013) Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. J. Surg. Oncol., 107, 555-559.
88. Rinn,J.L., Kertesz,M., Wang,J.K., Squazzo,S.L., Xu,X., Brugmann,S.A., Goodnough,L.H., Helms,J.A., Farnham,P.J., Segal,E. et al. (2007) Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell, 129, 1311-1323.
89. Tsai,M.C., Manor,O., Wan,Y., Mosammaparast,N., Wang,J.K., Lan,F., Shi,Y., Segal,E. and Chang,H.Y. (2010) Long noncoding RNA as modular scaffold of histone modification complexes. Science, 329, 689-693.
90. Gupta,R.A., Shah,N., Wang,K.C., Kim,J., Horlings,H.M., Wong,D.J.,Tsai,M.C., Hung,T., Argani,P., Rinn,J.L. et al. (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature, 464, 1071-1076.
91. Yang,Z., Zhou,L., Wu,L.M., Lai,M.C., Xie,H.Y., Zhang,F. and Zheng,S.S. (2011) Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann. Surg. Oncol., 18, 1243-1250.
92. Kogo,R., Shimamura,T., Mimori,K., Kawahara,K., Imoto,S., Sudo,T., Tanaka,F., Shibata,K., Suzuki,A., Komune,S. et al. (2011) Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res., 71, 6320-6326.
93. Chen,F.J., Sun,M., Li,S.Q., Wu,Q.Q., Ji,L., Liu,Z.L., Zhou,G.Z., Cao,G., Jin,L., Xie,H.W. et al. (2013) Upregulation of the long non-coding RNA HOTAIR promotes esophageal squamous cell carcinoma metastasis and poor prognosis. Mol. Carcinog., 52, 908-915.
94. Li,X., Wu,Z., Mei,Q., Guo,M., Fu,X. and Han,W. (2013) Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma. Br.J.Cancer, 109, 2266-2278.
95. Bhan,A., Hussain,I., Ansari,K.I., Kasiri,S., Bashyal,A. and Mandal,S.S. (2013) Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. J. Mol. Biol., 425, 3707-3722.
96. Kim,K., Jutooru,I., Chadalapaka,G., Johnson,G., Frank,J., Burghardt,R., Kim,S. and Safe,S. (2013) HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene, 32, 1616-1625.
97. Chiyomaru,T., Fukuhara,S., Saini,S., Majid,S., Deng,G., Shahryari,V., Chang,I., Tanaka,Y., Enokida,H., Nakagawa,M. et al. (2014) Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. J. Biol. Chem., 289, 12550-12565.
98. Wang,L. and Huang,H. (2013) EZH2 takes the stage when BRCA1 loses. Cell Cycle, 12, 3575-3576.
99. Castanotto,D., Sakurai,K., Lingeman,R., Li,H., Shively,L., Aagaard,L., Soifer,H., Gatignol,A., Riggs,A. and Rossi,J.J. (2007) Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res., 35, 5154-5164.
100. Vickers,T.A., Lima,W.F., Nichols,J.G. and Crooke,S.T. (2007) Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Res., 35, 6598-6610.
101. Miyagishi,M., Hayashi,M. and Taira,K. (2003) Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug. Dev., 13, 1-7.
102. Kretschmer-Kazemi Far,R. and Sczakiel,G. (2003) The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res., 31, 4417-4424.
103. Grunweller,A., Wyszko,E., Bieber,B., Jahnel,R., Erdmann,V.A. and Kurreck,J. (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res., 31, 3185-3193.
104. Hefner,E., Clark,K., Whitman,C., Behlke,M.A., Rose,S.D., Peek,A.S. and Rubio,T. (2008) Increased potency and longevity of gene silencing using validated Dicer substrates. J. Biomol. Tech., 19, 231-237.
105. Foster,D.J., Barros,S., Duncan,R., Shaikh,S., Cantley,W., Dell,A., Bulgakova,E., O'Shea,J., Taneja,N., Kuchimanchi,S. et al. (2012) Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo. RNA, 18, 557-568.
106. Dudek,H., Wong,D.H., Arvan,R., Shah,A., Wortham,K., Ying,B., Diwanji,R., Zhou,W., Holmes,B., Yang,H. et al. (2014) Knockdown of beta-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo. Mol. Ther., 22, 92-101.
107. Swayze,E.E., Siwkowski,A.M., Wancewicz,E.V., Migawa,M.T., Wyrzykiewicz,T.K., Hung,G., Monia,B.P. and Bennett,C.F. (2007) Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res., 35, 687-700.
108. Hagedorn,P.H., Yakimov,V., Ottosen,S., Kammler,S., Nielsen,N.F., Hog,A.M., Hedtjarn,M., Meldgaard,M., Moller,M.R., Orum,H. et al. (2013) Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther., 23, 302-310.
109. Peek,A.S. and Behlke,M.A. (2007) Design of active small interfering RNAs. Curr. Opin. Mol. Ther., 9, 110-118.
110. Reynolds,A., Leake,D., Boese,Q., Scaringe,S., Marshall,W.S. and Khvorova,A. (2004) Rational siRNA design for RNA interference. Nat. Biotechnol., 22, 326-330.
111. Birmingham,A., Anderson,E., Sullivan,K., Reynolds,A., Boese,Q., Leake,D., Karpilow,J. and Khvorova,A. (2007) A protocol for designing siRNAs with high functionality and specificity. Nat. Protoc., 2, 2068-2078.
112. Wang,X., Varma,R.K., Beauchamp,L., Magdaleno,S. and Sendera,T.J. (2009) Selection of hyperfunctional siRNAs with improved potency and specificity. Nucleic Acids Res., 37, e152.
113. Xu,Y., Zhang,H.Y., Thormeyer,D., Larsson,O., Du,Q., Elmen,J., Wahlestedt,C. and Liang,Z. (2003) Effective small interfering RNAs and phosphorothioate antisense DNAs have different preferences for target sites in the luciferase mRNAs. Biochem. Biophys. Res. Commun., 306, 712-717.
114. Pandey,S.K., Wheeler,T.M., Justice,S.L., Kim,A., Younis,H.S., Gattis,D., Jauvin,D., Puymirat,J., Swayze,E.E., Freier,S.M. et al. (2015) Identification and characterization of modified antisense oligonucleotides targeting dmpk in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J. Pharmacol. Exp. Ther., 355, 310-321.
115. Vickers,T.A. and Crooke,S.T. (2015) The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA. Nucleic Acids Res., 43, 8955-8963.
116. Herbert,M., Coppieters,N., Lasham,A., Cao,H. and Reid,G. (2011) The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. BMC Res. Notes, 4, e148.
117. Hasselblatt,P., Hockenjos,B., Thoma,C., Blum,H.E. and Offensperger,W.B. (2005) Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides. Nucleic Acids Res., 33, 114-125.